Hovione divestment marks its commitment to supplying highly specialized APIs

8 Mar 2018

Portuguese company exits the large volume business of contrast media to concentrate on its CDMO business.

Hovione has concluded the sale of all of the share capital of iMAX Diagnostic Imaging Holding Limited. For Hovione, this sale marks the end of 24 years of history of reliable and uninterrupted supply of iopamidol and iohexol API to the generic industry globally.

Hovione divestment marks its commitment to supplying highly specialized APIs

Hovione entered the generic contrast media business in 1993 and in 2007 moved most of its manufacture to the iMAX factory in China because its capacity in Europe was no longer able to meet clients’ demand. This business continued to show a steady profitable growth and for most of that period represented the largest tonnage of Hovione’s product portfolio. Over the course of these 20 years formulations containing Hovione’s contrast media have been supplied to the growing markets of Asia and have included Japan’s best selling generic medicine.

Faced with considerable opportunities in both the contrast agents business and all its other segments, Hovione decided to focus on its CDMO business, on its off-patent business supplying highly specialized APIs and to exit the large volume business of contrast media. The very significant expansion plans that Hovione has embarked upon since 2016 require all of our attention.

“Getting into iopamidol and iohexol was a decision we took in 1993. Today Hovione’s strategy focuses on difficult-to-make and difficult-to-formulate products, supplied to demanding markets, serving innovative clients. Our contrast media business is growing and has many loyal clients that demand high quality, but it increasingly does not seem a good fit with the rest of our activities. The opportunity to sell iMAX with its manufacturing business of APIs and formulated product to a market leader makes sure this business can continue to develop even better. We are convinced that the buyer will be good owner and employer, and will continue supplying reliably the great clients that have supported iMAX’s growth.” said Guy Villax, CEO.

Read More

Companies mentioned

Related tags

Market News

Related news

Pioneer in Phenylketonuria to begin clinical trial with gene therapy

Pioneer in Phenylketonuria to begin clinical trial with gene therapy

15 Jan 2020

BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.

Read more 
Catalent launches direct-to-patient clinical supply services

Catalent launches direct-to-patient clinical supply services

14 Jan 2020

Multiple options provide increased flexibility for sponsors.

Read more 
Biogen to acquire novel clinical-stage asset from Pfizer

Biogen to acquire novel clinical-stage asset from Pfizer

14 Jan 2020

PF-05251749 complements the company’s pipeline of potential disease-modifying therapies for Alzheimer’s and Parkinson’s diseases.

Read more 
French regulator agrees to partial resumption of Tellomak trial patient recruitment

French regulator agrees to partial resumption of Tellomak trial patient recruitment

14 Jan 2020

The French National Agency for Medicines and Health Product Safety (ANSM) has agreed that Innate Pharma’s Tellomak (lacutamab) Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) in ...

Read more 
Lupin could face FDA regulatory action over Tarapur API facility

Lupin could face FDA regulatory action over Tarapur API facility

13 Jan 2020

India’s Lupin Pharmaceuticals warned Monday it could face regulatory sanctions from the US Food and Drug Administration over its Tarapur active pharmaceutical ingredient (API) manufacturing facility.

Read more 
Partnership formed to develop and commercialise ready-to-use medicine

Partnership formed to develop and commercialise ready-to-use medicine

13 Jan 2020

The product being developed will use proprietary drug formulation technology platform Arestat to deliver new reformulations of existing, complex products.

Read more 
ReadCoor to commercially launch spatial sequencing platform

ReadCoor to commercially launch spatial sequencing platform

10 Jan 2020

Platform gives researchers access to previously undiscovered data to guide evaluation and validation of new drug targets, pathogen identification, disease diagnosis, and the advancement of regenerative medicine.

Read more 
CPhI and AAPS partner to expand expert scientific content at CPhI North America

CPhI and AAPS partner to expand expert scientific content at CPhI North America

10 Jan 2020

CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...

Read more 
Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

9 Jan 2020

The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.

Read more 
New HQ for developer of world's first fully automated drug discovery platform

New HQ for developer of world's first fully automated drug discovery platform

8 Jan 2020

End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.

Read more